Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer – – Comprehensive Business Update and Path to Initiating Phase 2 ...

Transcranial magnetic stimulation (TMS, or "rTMS" for "repetitive TMS") received an indication for treating major depressive disorder in 2008. Since then, research and clinical experience with TMS has ...

Cyclerion Therapeutics entered an agreement to integrate Medsteer's technology into CYC-126, its lead program in development for treatment-resistant depression.

GH Research ( ($GHRS) ) just unveiled an update. On January 5, 2026, GH Research announced that the U.S. Food and Drug Administration lifted the ...

Shares of Cyclerion Therapeutics climbed after the company entered an agreement to integrate Medsteer's technology into its lead program in development for treatment-resistant depression. The stock ...

A new study has found that antidepressant resistance is more common than was thought: 48% of people with depression have tried at least two medications without effect, while 37% have tried four or ...

Investing.com -- Cyclerion Therapeutics Inc (NASDAQ:CYCN) stock soared 44.2% in after-hours trading Monday following the announcement of a strategic collaboration with Medsteer to advance its ...

AUSTIN (KXAN)- Experts estimate that treatment-resistant depression (TRD) impacts about 2.8 million Americans annually, and a groundbreaking implantable device may offer new hope. Depression affects ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...